Amiodarone in Heart Failure: Are We Monitoring Enough?

Amiodarone is frequently used in patients with heart failure—particularly when atrial or ventricular arrhythmias coexist with reduced EF.

But prescribing amiodarone should probably come with something else: a monitoring plan.

The challenge is that several manifestations of amiodarone toxicity can look remarkably similar to worsening heart failure.

Dyspnea → HF congestion or amiodarone lung toxicity?

Fatigue → low-output HF or thyroid dysfunction?

Elevated liver enzymes → hepatic congestion or amiodarone toxicity?

Bradycardia → beta-blocker/GDMT effect or amiodarone?

That makes surveillance especially important in the HF population.

Before starting amiodarone

Consider establishing a baseline:

TSH ± free T4/T3 if abnormal

Liver function tests

ECG — rhythm, heart rate, QTc

Chest X-ray

Potassium and magnesium

Consider pulmonary function testing/DLCO when clinically appropriate

During chronic therapy

Every 6 months:

→ TSH

→ Liver function tests

→ Reassess whether amiodarone is still necessary

ECG surveillance:

→ Bradycardia

→ QT prolongation

→ Conduction disease

New cough or unexplained dyspnea:

→ Don’t automatically assume it’s CHF.

→ Consider amiodarone pulmonary toxicity and obtain appropriate chest imaging.

Routine serial PFT/DLCO screening in every asymptomatic patient is less clearly supported; current ACC/AHA AF guidance emphasizes baseline chest radiography and symptom-triggered evaluation, with CT particularly useful when unexplained cough or dyspnea develops.

Similarly, routine ophthalmologic screening isn’t necessarily required for everyone, but new visual symptoms warrant evaluation.

The bigger issue

In heart failure, medication toxicity can masquerade as progression of the disease itself.

Before escalating diuretics for unexplained dyspnea, attributing fatigue to advanced HF, or blaming abnormal LFTs on congestion—ask whether amiodarone could be contributing.

Amiodarone can be an extremely useful drug in selected HF patients.

But long-term amiodarone should rarely be a “prescribe it and forget it” medication.

#HeartFailure #Amiodarone #Cardiology #Electrophysiology #AtrialFibrillation #Arrhythmia #HFrEF #PatientSafety